Abstract
During the past 100 years, Rift Valley fever virus (RVFV), a mosquito-borne virus, has caused potentially lethal disease in livestock, and has been associated with significant economic losses and trade bans. Spillover to humans occurs and can be fatal. Here, we combined data on RVF disease in humans (22 countries) and animals (37 countries) from 1931 to 2020 with seroprevalence studies from 1950 to 2020 (N=226) from publicly available databases and publications to further the understanding of RVFV epidemiology. RVFV has spread from its original focus in Kenya throughout Africa. In 2000, RVFV was first detected in the Arabian peninsula. Since then seropositive animals have been observed in additional countries in western Asia. Throughout the study period, seroprevalence increased in both humans and animals, suggesting potentially increased RVFV exposure. Among ruminants, sheep were most likely to be exposed during RVF outbreaks, but not during periods of cryptic spread. Filling data gaps, detailed study descriptions (e.g., study population details, diagnostic test characteristics), and long-term studies using a one health approach will aid to further convert the patchwork of data to the tale of RFV epidemiology and inform surveillance and intervention strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by an award from the Coalition for Epidemic Preparedness Innovations to the University of Notre Dame. In addition, TAP received support from USDA-NIFA AFRI Grant 2019-67015-28982 as part of the joint USDA-NSF-NIH-BBSRC-BSF Ecology and Evolution of Infectious Diseases program. GMB is supported by the Wageningen University Graduate School, postdoc-talent grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data from previously published work was used.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be made available in Open Science Framework upon publication.
